Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 6721 AL 6735

[Sleep disorders in patients with a neurocognitive disorder]

Moderie C, Carrier J, Dang-Vu TT.

Encephale. 2022 Jun;48(3):325-334. doi: 10.1016/j.encep.2021.08.014. Epub 2021 Dec 14.

Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases

Pérez-Olives C, Rivas-Santisteban R, Lillo J, Navarro G, Franco R.

Adv Exp Med Biol. 2021;1264:81-92. doi: 10.1007/978-3-030-57369-0_6.

Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer's Disease

Kim J.

Int J Mol Sci. 2021 Mar 13;22(6):2929. doi: 10.3390/ijms22062929.

Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases

Trudler D, Ghatak S, Lipton SA.

Int J Mol Sci. 2021 Jul 30;22(15):8196. doi: 10.3390/ijms22158196.

CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics

Bhardwaj S, Kesari KK, Rachamalla M, Mani S, Ashraf GM, Jha SK, Kumar P, Ambasta RK, Dureja H, Devkota HP, Gupta G, Chellappan DK, Singh SK, Dua K, Ruokolainen J, Kamal MA, Ojha S, Jha NK.

J Adv Res. 2022 Sep;40:207-221. doi: 10.1016/j.jare.2021.07.001. Epub 2021 Jul 6.

Insight γ-Secretase: Structure, Function, and Role in Alzheimer's Disease

Mal S, Malik U, Pal D, Mishra A.

Curr Drug Targets. 2021;22(12):1376-1403. doi: 10.2174/1389450121999201230203709.

Cannabinoid receptor 2 selective agonists and Alzheimer's disease: An insight into the therapeutic potentials

Magham SV, Thaggikuppe Krishnamurthy P, Shaji N, Mani L, Balasubramanian S.

J Neurosci Res. 2021 Nov;99(11):2888-2905. doi: 10.1002/jnr.24933. Epub 2021 Sep 6.

Effects of Myricitrin and Relevant Molecular Mechanisms

Zhang X, Zhang K, Wang Y, Ma R.

Curr Stem Cell Res Ther. 2020;15(1):11-17. doi: 10.2174/1574888X14666181126103338.

Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool

Ha ZY, Mathew S, Yeong KY.

Curr Protein Pept Sci. 2020;21(1):99-109. doi: 10.2174/1389203720666191107094949.

Novel Therapeutics for the Treatment of Alzheimer's and Parkinson's Disease

Singh K, Yadav D, Chauhan PS, Mishra M, Jin JO.

Curr Pharm Des. 2020;26(7):755-763. doi: 10.2174/1381612826666200107161051.

Immunotherapy for Parkinson's disease

Schwab AD, Thurston MJ, Machhi J, Olson KE, Namminga KL, Gendelman HE, Mosley RL.

Neurobiol Dis. 2020 Apr;137:104760. doi: 10.1016/j.nbd.2020.104760. Epub 2020 Jan 21.

The Main Targets Involved in Neuroprotection for the Treatment of Alzheimer's Disease and Parkinson Disease

Gülcan HO, Orhan IE.

Curr Pharm Des. 2020;26(4):509-516. doi: 10.2174/1381612826666200131103524.

Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer's, Parkinson's and Prion's

Nirale P, Paul A, Yadav KS.

Life Sci. 2020 Mar 15;245:117394. doi: 10.1016/j.lfs.2020.117394. Epub 2020 Feb 1.

A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease

Ettcheto M, Busquets O, Espinosa-Jiménez T, Verdaguer E, Auladell C, Camins A.

Curr Pharm Des. 2020;26(12):1286-1299. doi: 10.2174/1381612826666200211121416.

Healthy Effects of Plant Polyphenols: Molecular Mechanisms

Leri M, Scuto M, Ontario ML, Calabrese V, Calabrese EJ, Bucciantini M, Stefani M.

Int J Mol Sci. 2020 Feb 13;21(4):1250. doi: 10.3390/ijms21041250.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias